Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Hologic Inc (HOLX) reports a 1% revenue increase with robust diagnostics performance, while facing headwinds in breast health ...

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Hologic Inc (NASDAQ:HOLX). reported its financial results for the first quarter of fiscal year 2025, showing a slight beat in earnings per share (EPS) but falling short on revenue expectations. The ...

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.

MARLBOROUGH, Mass. - Medical (TASE:PMCN) technology company Hologic, Inc. (NASDAQ:HOLX) reported mixed fiscal first quarter results and provided weaker-than-expected guidance for the current quarter, ...

The stock's rise snapped a three-day losing streak.

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...